Hengrui Medicine's Carrelizumab was approved for the world's first first-line nasopharyngeal cancer indication

Carrelizumab has another good news

Significantly prolong the progression-free survival of patients with advanced nasopharyngeal carcinoma

Nasopharyngeal carcinoma is one of the most common tumors in China, and 50% of nasopharyngeal carcinomas in the world occur in China

The approval of carrelizumab for nasopharyngeal carcinoma is based on the CAPTAIN-1ST study led by Professor Zhang Li from the Cancer Center of Sun Yat-sen University

A total of 263 subjects were enrolled in this study, all patients with late recurrence or metastasis, all with distant metastasis, were randomly enrolled according to 1:1, and the enrolled subjects received carrelizumab.

Carrelizumab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma is expected to become the new standard treatment for locally advanced recurrent/metastatic advanced nasopharyngeal carcinoma, which will enable more advanced noses Patients with pharyngeal cancer benefit

Carrelizumab shines at ASCO annual meeting

Prior to this, Carrelizumab had been approved by the NMPA in May 2019 for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma who had undergone at least second-line chemotherapy; obtained in March 2020 NMPA is approved for the treatment of patients with advanced hepatocellular carcinoma who have received sorafenib treatment and/or oxaliplatin-containing system chemotherapy; in June 2020, it was approved by NMPA in combination with pemetrexed and carboplatin for epidermal growth First-line treatment for non-squamous non-small cell lung cancer (NSCLC) that is negative for factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) negative, unresectable, locally advanced or metastatic; obtained in June 2020 NMPA is approved for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma patients with disease progression or intolerance after previous first-line chemotherapy; NMPA approved in April 2021 for the treatment of disease progression or after previous second-line chemotherapy or above Treatment of intolerable advanced nasopharyngeal carcinoma patients

Since the advent of carrelizumab, clinical research results have been on the stage of international academic conferences many times, and clinical research in the fields of nasopharyngeal cancer, liver cancer, esophageal cancer, lung cancer and other fields have reached the top of the Lancet series of journals.

Benefiting people's livelihood: 4 major indications have entered medical insurance

For immunotherapeutic drugs, in addition to expanding indications and overcoming technical difficulties, lowering prices for medical insurance on the basis of excellent curative effects will also help make innovative drugs better benefit the people's livelihood

As the leader of national medicine innovation, Hengrui Medicine has been adhering to the original research for many years, and is committed to providing good "weapons" for Chinese doctors and providing more treatment opportunities for Chinese patients

The follow-up research and development of karelizumab not only focuses on the combination of existing indications and cancer types, but also focuses on the expansion of indications for other cancer types.